http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014140343-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4816 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4891 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 |
| filingDate | 2013-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014140343-A |
| titleOfInvention | CAPSULE COMPOSITION |
| abstract | 1. Capsule composition containing encapsulated material containing {[(1R, 2R) -2- [4- (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1 - (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} methyldihydrophosphate, or a pharmacologically acceptable salt thereof, or a solvate of any of the aforementioned gelatin-free capsule capsules. 2. Capsule composition according to claim 1, characterized in that the capsule shell is formed by the base of the capsule shell containing starch, pullulan, polyvinyl alcohol or hypromellose. 3. Capsule composition according to claim 1, characterized in that the capsule shell is formed by the base of the capsule shell containing pullulan or hypromellose. The capsule composition according to claim 1, characterized in that the capsule shell is formed by the base of the capsule shell containing hypromellose. Capsule composition according to any one of paragraphs. 1-4, characterized in that {[(1R, 2R) -2- [4- (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} methyldihydrophosphate, or a pharmacologically acceptable salt thereof, or a solvate of any of the above is L-lysine - {[{1R, 2R) -2- [4 - (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} methyl dihydrogen phosphate ethanol (1/1/1) .6. Capsule composition according to any one of paragraphs. 1-4, characterized in that the encapsulated material further comprises magnesium oxide. The capsule composition according to claim 5, characterized in that the encapsulated material further comprises magnesium oxide. |
| priorityDate | 2012-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.